Laura Deming: The Longevity Fund pitched Unity Biotechnology to secure early LPs
Laura Deming · 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund · Nov 26, 2018 · at 19:47
Laura Deming, Founding Partner at The Longevity Fund, discusses the breakthrough moment when pitching early limited partners for her first fund.
0:00 / 0:13exact quote · 13.8s
720p mp4 · rendered on demand · StarZero watermark
“We had just found one of the first companies that we ever invested in, Unity Biotechnology, and we were really, really excited about them. And so I actually used that as the first Deal that I discussed with LPs.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Laura Deming
Deming: Longevity is counterintuitively the least risky sector in biology
“I literally thought it was the least risky, most likely to work part of biology in general, particularly the part of biology that would be easy to test in humans, and that's very counterintuitive to most people.”
Deming: Biotech VC is constrained by founder talent, not funding
“And so I think the fascinating thing is, you know, I always assumed from the outside that biotech venture capital was really limited by dollars, and I think it used to be, but I think the fascinating fact is now it's all about talent, and just, you know, we're…”
Deming: Biotech value stems from founder-driven decisions, not initial thesis
“And I think, you know, maybe sometimes focusing on the thesis of an investment can blind you to the fact that most of the value in biotech comes from the eventual trajectory of the company that's unpredictable at the start. And that trajectory is absolutely di…”
Deming: Biotech VC funding doubled while new startup creation remained flat
“I think one of the founding into biotech venture capital has doubled over the past couple years, and that's a huge fact, but the number of companies started to stay fairly stable”
Deming: All Longevity Fund portfolio companies target multi-disease pathways
“All the companies that we invest in have drugs that have worked not just in kind of mouse models of Alzheimer's typically, but also diabetes and heart disease, and kind of typically the pathways that we invest in have been tested in and work in almost every Ag…”
Deming: VC value creation is limited by rigid fund structure norms
“I think the diversity of fun types. I think we've been artificially constrained by a perception that it's hard to raise a new structure of fun because LPs just kind of, like, amorphously won't like it. I think that's really cut down on the value to be created …”